BPAP

The cleanest theoretical successor to selegiline that exists on paper — pure catecholaminergic (and serotonergic) activity enhancer via TAAR1, no MAO inhibition at relevant doses, ~130× more potent than selegiline in rat models, with longer rat lifespans + striking tumor-suppression data + cognitive-aging-reversal signal at sub-microgram-per-kg doses. But: zero published human RCT data, one apparently-stalled Fujimoto Phase 2 Parkinson's program, research-chem-only sourcing where ≥97% purity matters at sub-mg dosing, and the benzofuran scaffold carries unresolved liver-safety questions at the class level. For Dylan, this is a "WATCH-LIST until human data exists" — not a stack candidate today, but a real candidate to watch as the V5 plan matures and the Fujimoto program either reports out or dies.

What "catecholaminergic activity enhancer" (CAE) actually means

Knoll coined this term to describe a class of mechanism that's neither amphetamine-like (forced release) nor MAOI-like (block degradation). A CAE / MAE (monoaminergic activity enhancer — broader category) does NOT:

• Force neurons to dump their vesicle contents (amphetamine, methamphetamine)
• Block reuptake at the transporter (cocaine, methylphenidate, modafinil)
• Block degradation enzymes (selegiline at MAO-B, phenelzine at MAO-A+B)

What it DOES do: when a neuron's normal pacemaker firing generates an action potential, the CAE amplifies the amount of neurotransmitter released per impulse. Resting release is roughly unchanged. The pattern of who fires when is unchanged. The drug effect is physiologically gated — it tracks endogenous neuronal demand rather than overriding it. Result: no supraphysiologic synaptic flood, no D2 downregulation, no tolerance via that pathway, no comedown from depleted vesicle pools.

BPAP is the cleanest example of this mechanism in the catecholamine + serotonin space

• Selegiline: CAE activity is secondary — primary mechanism is irreversible MAO-B inhibition. The CAE component requires sub-MAO-inhibitory doses to be the dominant effect, and even then is layered on top of permanent enzyme suicide-inhibition.
• PPAP (the parent compound, predecessor to BPAP): pure CAE, no MAO inhibition, but only enhances dopamine + norepinephrine. Less potent. Recent 2025 work also flagged it as a meaningful catecholamine reuptake inhibitor at high doses, complicating the "pure CAE" framing.
• BPAP: Pure CAE/SAE — enhances dopamine + norepinephrine + serotonin. ~130× more potent than selegiline in standardized rat shuttle-box and tetrabenazine-reversal models. MAO-A inhibition exists but is ~10,000× weaker than clorgyline (clinically irrelevant at any plausible therapeutic dose). At very high doses BPAP becomes a monoamine reuptake inhibitor (DAT IC₅₀ ~16-42 nM, NET IC₅₀ ~52-211 nM, SERT IC₅₀ ~640 nM) but these effects sit "well above its MAE actions" — the therapeutic dose is in the picomolar-femtomolar range while reuptake-relevant concentrations are nanomolar.

TAAR1 is the proximate molecular target (best current evidence)

The mechanism that puzzled Knoll for decades has been progressively clarified through the 2020s:

1. BPAP enters the presynaptic neuron via the monoamine transporter (DAT, NET, or SERT depending on cell type)
2. Inside the cell, BPAP activates intracellular TAAR1 (trace amine-associated receptor 1)
3. TAAR1 signaling potentiates VMAT2 (vesicular monoamine transporter 2)-mediated vesicle loading + impulse-coupled release
4. Net effect: when an action potential arrives, more transmitter is released per vesicle exocytosis event

Evidence supporting this model:

• EPPTB (selective TAAR1 antagonist) reverses BPAP's MAE effects (and selegiline's CAE effect) — strong pharmacological proof of TAAR1 dependence
• 3-F-BPAP (a structural analog with weak MAE activity) antagonizes BPAP's effect, suggesting same binding site
• 2025 Springer Neurochemical Research paper (Regulation by TAAR1 of dopaminergic-GABAergic interaction in the striatum: effects of (-)BPAP) explicitly maps the BPAP → TAAR1 → striatal DA → GABAergic output pathway and confirms TAAR1 as a triggering element in both vesicular and non-vesicular DA release, with BPAP specifically potentiating the vesicular component

Bimodal bell-shaped dose-response — the critical kinetic feature

All MAEs including BPAP show two distinct bell-shaped activity peaks across the dose range. Knoll called these the "specific" and "non-specific" enhancer effects:

• "Specific" enhancer effect: lower-dose peak (e.g., BPAP 0.0001 mg/kg in rats — sub-microgram). Sharp narrow peak. Likely reflects TAAR1-mediated mechanism in its cleanest form.
• "Non-specific" enhancer effect: higher-dose peak (e.g., BPAP 0.05 mg/kg in rats). Broader peak. Likely involves additional mechanisms (some reuptake inhibition, broader receptor crosstalk).

Practical consequence: there's a narrow "Goldilocks" concentration window for optimal effect, and going higher does not give more effect (and may give less). This makes accurate dosing critical and is the central reason research-chem identity + concentration verification matters more for BPAP than for almost any other compound in the encyclopedia.

How this differs from selegiline (the "cleaner mechanism" claim — verified)

The "cleaner selegiline" framing is mechanistically defensible and roughly accurate:

The key trade: BPAP gives up the irreversible MAO-B inhibition (which IS part of why selegiline preserves DA over decades) in exchange for cleaner mechanism + broader monoamine coverage + dramatically higher CAE potency. Whether that's net-better depends on whether you wanted MAO-B inhibition in the first place. For a 20yo brain-priority user, the MAO-B inhibition's value comes mostly from animal lifespan data — which BPAP also has, in the same animals, at lower doses.